|Bid||0.365 x 0|
|Ask||0.380 x 0|
|Day's Range||0.370 - 0.370|
|52 Week Range||0.335 - 0.485|
|Beta (3Y Monthly)||0.21|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Investors are always looking for growth in small-cap stocks like Innovative Pharmaceutical Biotech Li...
If you're interested in Innovative Pharmaceutical Biotech Limited (HKG:399), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stockRead More...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Innovative Pharmaceutical Biotech Limited Read More...
After reading Innovative Pharmaceutical Biotech Limited’s (HKG:399) most recent earnings announcement (30 September 2018), I found it useful to look back at how the company has performed in the past Read More...
Nov 29 (Reuters) - Innovative Pharmaceutical Biotech Ltd : * HY LOSS ATTRIBUTABLE HK$171.3 MILLION VERSUS LOSS OF HK$146.7 MILLION * HY REVENUE HK$10.1 MILLION VERSUS HK$9.7 MILLION Source text for Eikon: ...
Singapore state investor Temasek Holdings cautioned it was looking to temper its pace of investments this year as trade tensions between world's top two economies ratchet up, after reporting a record high annual portfolio value. The cautious outlook underlines the challenges that state investment firms like Temasek face as rising protectionist policies and anti-globalization sentiments put their investment and risk management capabilities to test.
June 29 (Reuters) - Innovative Pharmaceutical Biotech Ltd : * FY REVENUE HK$15.8 MILLION VERSUS HK$9.2 MILLION * LOSS FOR YEAR ATTRIBUTABLE HK$231.0 MILLION VERSUS LOSS OF HK$169.8 MILLION Source text ...